An Open-Label, Three-Cohort, Phase 2 Study of E7080 (Lenvatinib) in Subjects With Recurrent Malignant Glioma
Phase of Trial: Phase II
Latest Information Update: 30 May 2016
At a glance
- Drugs Lenvatinib (Primary) ; Bevacizumab
- Indications Glioblastoma; Glioma
- Focus Therapeutic Use
- Sponsors Eisai Co Ltd
- 20 May 2016 Status changed from discontinued to completed.
- 27 Dec 2013 Actual study completion date added as reported by ClinicalTrials.gov record.
- 26 Dec 2013 Status changed from active, no longer recruiting to discontinued, as per ClinicalTrials.gov..